Novo Nordisk’s Stock Surge: A Glimpse into the Future of Obesity Drugs?
(SeaPRwire) – By: Christian Pierce Novo Nordisk (NVO) has long grappled with a growth deadlock in 2026. The stock was down about 12.90% year – to – date, causing anxiety among investors. But on June 22, a significant jump
More